Goldline Pharmaceutical Ltd.
SMEPrice Range
₹41–43
Issue Size
₹ 8 Cr
Lot Size
6000 Shares
Min. Investment
₹ 2,46,000
Financial Summary
(in crores)| Particulars | FY 2024-25 | FY 2023-24 |
|---|---|---|
| Operating Revenue | 2,805.57 | 2,356.6 |
| Other Income | 0 | 0 |
| Total Income | 2,805.57 | 2,356.6 |
| Total Expenses | 2,199.98 | 1,926.18 |
| Profit Before Tax | 385.84 | 252.69 |
| Total Profit | 283.42 | 180.6 |
Subscription Details
Subscription
IPO Timeline
IPO Offer Start
12 May 2026
IPO Offer Ends
14 May 2026
Listing Date
19 May 2026
Use of Proceeds
| # | Purpose | Amount (₹ Cr) |
|---|---|---|
| 1 | Prepayment or repayment of all or a portion of certain outstanding borrowings availed by our company | 83.545 |
| 2 | General corporate purposes | 17.055 |
Promoters
Promoter Shareholding
Pre-IPO
79.70%
Promoter stake
Post-IPO
57.29%
Promoter stake
Offered to Public
19,68,000
shares
Post Share Capital
54,99,982
shares
About the Company
We are engaged in the business of marketing pharmaceutical products under the brand name “Goldline.” Our product portfolio is organized into five distinct segments: Goldline Pharma, Goldline Cardinal, Goldline Aayushman, Goldline InLife, and Goldline Wellness. The pharmaceutical products marketed under the “Goldline” brand are not manufactured by our Company. Instead, we enter into contractual arrangements with third-party manufacturers, who produce the products based on our market research, demand analysis, and specifications. These contractual arrangements ensure that all products meet the requisite quality standards and regulatory norms.The products are marketed and sold exclusively under the “Goldline” brand. Our customers primarily comprise distributors, who further supply to retailers and wholesalers, forming the main channel of distribution to the end-users. Presently, we maintain contractual arrangements with 15 manufacturers and 7 distributors, ensuring a stable supply chain and consistent market presence.Our Company also extend comprehensive material supply and procurement support to hospitals and healthcare partners. Through our promoter group entities as Numerius Healthcare Pvt Ltd (Formerly Known As Enrich Healthcare & PSPL International) & Activista Healthcare Pvt Ltd (Formerly Known As Gold N Gold Distributors). Our Company manage trading and supply chain operations, thereby ensuring reliable procurement, seamless distribution, and logistical efficiency.Our Promoters, Mr. Amol Laxmikant Mujumdar and Mr. Swapan Premprakash Khandelwal, with 25 years and 30 years of experience respectively in pharmaceutical marketing and supply chain management, have been instrumental in shaping the growth and strategic direction of the Company. Their expertise continues to drive our business expansion and operational resilience.
Use of Proceeds
1. Prepayment or repayment of all or a portion of certain outstanding borrowings availed by our Company; and2. General corporate purposes.